$AMTX

AEMETIS, INC (AMTX): Results of Operations and Financial Condition

AEMETIS, INC (AMTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_998023.htm EXHIBIT 99.1 AEMETIS Q2'2026 EARNINGS ex_998023.htm Exhibit 99.1 External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Company Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemeti

Original reporting
Published Aug 6, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AMTX
Bullish
medium confidence
Mentioned
$AMTX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AMTXBullishMed
01

Why it matters

The filing provides quantified earnings and operating metrics, including revenue growth, gross profit turnaround, adjusted EBITDA improvement, RNG volume growth, and forward-looking operational milestones (digesters expected to be commissioned in Q3). It also discloses balance-sheet stress via low cash and ongoing interest expense, which can affect near-term valuation and risk appetite.

02

Market read

Traders can update models for AMTX based on the disclosed earnings metrics, credit-driven revenue recognition, RNG volume ramp, and the cash/interest risk profile.

03

What to watch

Ethanol gross profit improvement is partly credit-driven (45Z) and corn input costs; traders should separate underlying margin trends from credit recognition and watch for LCFS pathway approval timing into Q3.

Relevance 7/10Novelty 7/10Timing: filed pre-market today, earnings call at 11:00 a.m. PT

Background

This is an SEC 8-K (Item 2.02) with Exhibit 99.1 covering Aemetis’ Q2 2026 financial results and operating updates across California ethanol and dairy RNG, plus India biodiesel commentary.

Company-level read

Ticker impact

$AMTXBullishMedium confidence
Context

Aemetis reported Q2 2026 results with $62.7M revenue, $13.5M gross profit, and improved adjusted EBITDA, plus biogas volume growth and LCFS pathway updates.

Expected impact

Near-term bias positive on earnings quality and RNG growth, with follow-through dependent on cash burn and LCFS/45Z renewals.

Evidence & confidence

The filing discloses multiple quantified operating improvements (revenue, gross profit, operating income, adjusted EBITDA) and specific operational catalysts (biogas volumes, digesters expected in Q3, LCFS pathways). However, it also highlights cash at $1.0M and elevated interest expense, which can cap upside and increase volatility.

Market effects

Reinforces demand and economics for RNG and renewable fuels tied to LCFS and production tax credits, potentially supporting sentiment toward similar credits-driven operators.

California ethanol and dairy RNG execution is a key driver, which may influence regional renewable fuels expectations.

India biodiesel commentary suggests ongoing sensitivity to Indian OMC purchasing cycles, relevant for cross-border biofuel demand.

Counterpoint

Despite operating improvement, the company’s cash balance fell to $1.0M and interest expense remains large, so equity risk may rise if credit economics or project timelines slip.

Key entities

  • Aemetis, Inc.

    Renewable natural gas and renewable fuels company reporting Q2 2026 results and operating updates in an SEC 8-K.

  • Aemetis Biogas LLC

    Biogas/RNG operating entity referenced for preferred unit accretion and interest-related expenses.

  • Keyes ethanol plant

    California ethanol facility where a mechanical vapor recompression project is underway to reduce fossil natural gas usage.

Related articles

$AMTXMed

Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart

Aemetis reported Q2 2026 revenue of $62.7 million, up $10.5 million (20%) from Q2 2025, including $8.6 million from Section 45Z tax credits. Operating income improved by $16.4 million, net loss narrowed to $9.4 million, and adjusted EBITDA rose to $9.7 million. The company is pursuing refinancing and financing for its Keyes ethanol and Dairy RNG projects, and is considering an IPO for its India unit.

$AMTXMed

Aemetis stock rises on India biodiesel supply deal

Aemetis Inc (NASDAQ:AMTX) shares rose 4.3% after its India unit, Universal Biofuels, secured about $17 million in biodiesel supply contracts. Over three months it will deliver more than 18 million liters to India’s three government-owned Oil Marketing Companies, supporting a policy to raise biodiesel blending to 5% by 2030. Additional orders are expected through 2026.

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.